ALPHA
Phase 1 Completed
50 enrolled
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase 1/2 Completed
87 enrolled 24 charts
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1 Completed
54 enrolled 24 charts
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
FluBuATG
Phase 1 Completed
20 enrolled
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
Phase 2 Completed
22 enrolled 15 charts
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
BMT CTN 0903
Phase 2 Completed
20 enrolled 25 charts
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase 2 Completed
82 enrolled 18 charts
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2 Completed
49 enrolled 21 charts
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Phase 1/2 Completed
43 enrolled 19 charts
HaploOnly
Phase 1 Completed
74 enrolled
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Phase 3 Completed
224 enrolled 30 charts
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Phase 1 Completed
7 enrolled
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Phase 1 Completed
5 enrolled
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Phase 2 Completed
33 enrolled 4 charts
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase 2 Completed
295 enrolled 27 charts
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Phase 3 Completed
210 enrolled 14 charts
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Phase 2 Completed
22 enrolled 5 charts
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Phase 1 Completed
28 enrolled
Autologous and Allogeneic Transplant for Relapsed Lymphoma
Phase 1/2 Completed
30 enrolled 12 charts
Reduced Intensity Double Umbilical Cord Blood Transplantation
Phase 2 Completed
33 enrolled 19 charts
MCLPIII
Phase 2/3 Completed
370 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Tandem Auto-Allo Transplant for Lymphoma
Phase 2 Completed
42 enrolled 18 charts
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase 4 Completed
72 enrolled 10 charts
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Phase 2 Completed
56 enrolled 10 charts
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase 2 Completed
96 enrolled 5 charts
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Phase 2 Completed
29 enrolled 6 charts
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Phase 1 Completed
5 enrolled
Cellular Therapy With Cord Blood Cells
Phase 2 Completed
31 enrolled 6 charts
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Phase 1/2 Completed
82 enrolled 6 charts
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
Phase NA Completed
65 enrolled